@rmondello I have a little snippet I put together recently in another context, quotes are from the OPM website or carrier letters:
> in 2014, OPM issued Carrier Letter 2014-04 clarifying that it is not permissible to exclude weight loss drugs from FEHB coverage on the basis that obesity is a “lifestyle” condition and not a medical one or that obesity treatment is “cosmetic.”
> In Carrier Letter 2022-03, OPM stated that FEHB Carriers are not allowed to exclude anti-obesity medications from coverage based on a benefit exclusion or a carve out. Carrier Letter 2022-02 outlines the requirements for NonDiscriminatory Formulary Design, namely, that a non-discriminatory formulary design does not have cost or access barriers imposed by disease or condition.
> As new anti-obesity drugs are approved by the FDA, OPM expects Carriers to evaluate and update their coverage of anti-obesity drugs.
The "letters" being referenced are available on the OPM website: https://www.opm.gov/healthcare-insurance/carriers/fehb
AFAIK these letters were issued as a result of union action, but I haven't confirmed that.